Home 2018-05-22T18:26:57+00:00


At M4K Pharma, we are using open science to revolutionize how affordable new treatments are discovered and developed. Through our Medicines4Kids program, we will aggregate and align the work of global academics, foundations and industry researchers to advance new cures for childhood diseases not well-served by current business models.

Liz Brown @thesgconline develops an assay to verify that ALK2 inhibitors leading to #DIPG and #FOP drugs alter the BMP signalling pathway. #Openscience notebook record: https://t.co/9NH9NLDodS Accompanying blog: https://t.co/u41KStIdNn @ifopa @DefeatDIPG @FOPFriends

Missed our June Scientific Update meeting? Listen to a recording of the meeting's discussions here: https://t.co/hBQfPeTaVR

Thanks to @thesgconline for the opportunity to share how @BrainTumourOrg are working with @M4KPharma and others on #DIPG #collaboration

Ellie Williams @thesgconline tests the selectivity of ALK2 inhibitors from @M4KPharma towards the discovery of a drug for the paediatric brain tumour #DIPG and the skeletal disorder #FOP. #Openscience notebook: https://t.co/AMfXk9GirN Accompanying blog: https://t.co/X1wtZ5g5Rb

Both heart-warming and heart-breaking story today about brave Lola in @washingtonpost. She had #dipg. Only makes us at @M4KPharma try harder to make a difference. @CRiverLabs @ReactionBiology @OICR_news @BrainTumourOrg #opendrugdiscovery

Load More...

Latest Blog Posts